Biologics for HS

Hidradenitis suppurativa, usually shortened to HS, is one of those conditions that sounds like it should come with a small instruction manual, a dermatologist on speed dial, and maybe a loyalty card for soft clothing. It is a chronic inflammatory skin disease that can cause painful nodules, abscesses, drainage, tunnels under the skin, scarring, and flares that seem to arrive with the timing of an uninvited group chat. For many people, HS appears in areas where skin rubs together, such as the underarms, groin, buttocks, inner thighs, and under the breasts.

The important thing to know right away is this: HS is not caused by poor hygiene, and it is not simply “bad acne.” It is driven by inflammation, immune system activity, genetics, hormones, friction, and other factors that can vary from person to person. That is why treatment often needs to be more sophisticated than washing harder, switching deodorant for the 47th time, or pretending loose sweatpants are a complete medical strategy.

For moderate-to-severe HS, biologics have changed the conversation. These medications target specific parts of the immune system that help fuel inflammation. They are not magic wands, and they do not work for everyone, but they can reduce flares, pain, inflammatory nodules, and disease progression for many patients. In the United States, FDA-approved biologic options for HS now include adalimumab, secukinumab, and bimekizumab for eligible patients. That makes today’s HS treatment landscape much more hopeful than it was a decade ago.

What Are Biologics for HS?

Biologics are medicines made from living cells or biological materials. Instead of broadly suppressing the entire immune system like a giant “mute all” button, they target specific inflammatory pathways. In HS, the goal is to calm the overactive inflammatory signals that help create painful lesions, swelling, drainage, and recurring flares.

Think of HS inflammation like a kitchen smoke alarm that keeps screaming even when nobody is burning toast. Biologics try to quiet certain parts of that alarm system. They do not erase HS overnight, but they can help turn down the inflammatory volume so the skin has a better chance to heal and stay calmer.

Why Biologics Matter in Hidradenitis Suppurativa

HS can become more difficult to manage when inflammation continues for years. Repeated flares may lead to scar tissue, sinus tracts, limited movement, odor, drainage, and serious quality-of-life problems. Many people with HS also deal with embarrassment, anxiety, missed work or school, and the exhausting emotional math of choosing clothes based on pain level rather than style. HS is not just a skin problem; it can affect sleep, confidence, relationships, exercise, and everyday planning.

Traditional HS treatments can include topical antibiotics, oral antibiotics, steroid injections, hormonal therapy, pain management, antiseptic washes, laser procedures, deroofing, excision, and lifestyle changes such as reducing friction and quitting smoking. These options still matter. In fact, HS care is often a “team sport,” with medications, procedures, wound care, and daily habits working together. But when HS is moderate to severe, keeps returning, or does not respond well enough to older treatments, biologic therapy may become a major option.

FDA-Approved Biologics for HS

As of the current U.S. treatment landscape, the main FDA-approved biologics for hidradenitis suppurativa are adalimumab, secukinumab, and bimekizumab. Each works differently, which is helpful because HS does not behave the same way in every patient.

Adalimumab: The Longtime TNF-Alpha Blocker

Adalimumab was the first FDA-approved biologic for moderate-to-severe HS. It targets tumor necrosis factor-alpha, often called TNF-alpha, a protein involved in inflammation. By blocking TNF-alpha, adalimumab can help reduce inflammatory lesions and flare activity in some people with HS.

Adalimumab has the longest track record among HS biologics. Dermatologists have used it for years, which means there is substantial real-world experience with its benefits, limits, monitoring needs, and insurance process. It is usually given as a subcutaneous injection, meaning it goes under the skin rather than into a vein. Patients are typically taught how to inject it at home, though the first few doses may feel like a tiny medical ceremony involving alcohol wipes, deep breathing, and pretending not to look nervous.

Because adalimumab affects immune activity, doctors usually screen for infections such as tuberculosis and hepatitis before starting treatment. They also review vaccination status, medical history, pregnancy plans, other immune-related conditions, and current medications.

Secukinumab: Targeting IL-17A

Secukinumab is an interleukin-17A inhibitor, also called an IL-17A blocker. IL-17A is one of the inflammatory cytokines believed to play a role in HS. Secukinumab expanded the HS biologic toolbox by giving patients and dermatologists another targeted option beyond TNF-alpha inhibition.

This matters because some patients do not respond well enough to one biologic, lose response over time, or cannot use a specific drug because of side effects or medical history. Having more than one approved pathway gives clinicians more room to personalize treatment. Secukinumab is also given by injection, and the exact schedule depends on the prescribing information and the patient’s treatment plan.

Like other biologics, secukinumab requires medical screening and monitoring. Doctors may ask about inflammatory bowel disease, recurrent infections, and other immune-related concerns before prescribing it. This is not because the medicine is “scary,” but because biologics are powerful tools, and powerful tools deserve a careful instruction manual.

Bimekizumab: Dual IL-17A and IL-17F Inhibition

Bimekizumab is a newer biologic option for adults with moderate-to-severe HS. It targets both IL-17A and IL-17F, two inflammatory proteins involved in immune signaling. This dual-target approach is one reason bimekizumab has attracted attention in HS treatment discussions.

The approval of bimekizumab added another important choice for adults living with moderate-to-severe HS, especially in a field where treatment options were limited for many years. For patients who have already tried antibiotics, procedures, topical care, or another biologic without enough improvement, newer targeted therapies may offer fresh possibilities. That said, “newer” does not automatically mean “best for everyone.” The right biologic depends on disease severity, medical history, age, insurance coverage, pregnancy considerations, infection risk, and patient preference.

Who May Be a Candidate for Biologic Therapy?

Biologics are usually considered for people with moderate-to-severe HS, especially when the condition causes recurring painful nodules, abscesses, draining tunnels, scarring, or major quality-of-life disruption. A dermatologist may also consider biologics when topical treatments, oral antibiotics, hormonal therapy, or procedures have not provided enough control.

Doctors often look at several factors before recommending a biologic: how many inflammatory nodules are present, whether abscesses or tunnels exist, how often flares occur, how much pain the patient has, whether scarring is progressing, and how HS affects daily life. Two people can have the same number of bumps but very different levels of pain, fatigue, drainage, and emotional stress. Good HS care pays attention to the whole picture, not just a quick glance at the skin.

What to Expect Before Starting a Biologic

Before starting biologic treatment for HS, a healthcare provider will usually review medical history, current symptoms, past treatments, allergies, infection history, and other diagnoses. Screening tests may include tuberculosis testing and hepatitis testing. Some patients may need updated vaccines before treatment begins, because certain live vaccines are generally avoided during biologic therapy.

This preparation stage can feel slow, especially when HS is already making life uncomfortable. But it helps reduce avoidable risks. It also gives the patient and clinician time to set realistic goals. A biologic may reduce flares, pain, drainage, and inflammation, but it may not erase old scarring or fully close established tunnels. In some cases, surgery or laser treatment may still be needed alongside medication.

How Fast Do Biologics Work for HS?

Some patients notice changes within weeks, while others need several months before the benefits become clear. HS is stubborn; it does not always read the brochure. Clinical trials often measure response around 12 to 16 weeks, but real-life treatment decisions may take longer, depending on the medication, symptom pattern, and patient progress.

It is helpful to track symptoms before and after starting treatment. Patients can record flare frequency, pain level, drainage, number of active areas, menstrual-cycle patterns, clothing limitations, missed activities, and side effects. Photos may help too, as long as they are stored privately and used for medical tracking. A symptom journal turns “I think it might be better?” into more useful information for the dermatologist.

Possible Side Effects and Safety Considerations

Because biologics affect immune pathways, they can increase the risk of infections. Some people may experience injection-site reactions, headache, upper respiratory symptoms, or other side effects depending on the medication. Specific risks vary by biologic. For example, TNF-alpha inhibitors and IL-17 inhibitors have different safety profiles, warnings, and monitoring considerations.

Patients should tell their healthcare provider about fevers, persistent cough, unusual fatigue, painful urination, wounds that do not heal, or symptoms that feel out of the ordinary. They should also discuss pregnancy, breastfeeding, upcoming surgery, dental procedures, travel plans, and vaccines. Biologic therapy is not a “set it and forget it” subscription box. It works best with follow-up appointments and honest communication.

Biologics Are Usually Part of a Bigger HS Plan

Even when a biologic works well, HS care often includes additional strategies. Patients may still need wound care, pain control, antibacterial washes, loose clothing, friction reduction, stress management, smoking cessation support, weight-related counseling if relevant, and procedures for persistent tunnels or scarred areas. None of these steps means the biologic has failed. HS is simply complicated enough to require a toolbox instead of a single shiny hammer.

For example, a patient might use a biologic to reduce new inflammatory flares while also having deroofing for an old tunnel that keeps draining. Another patient may use hormonal therapy with a biologic if flares clearly worsen around menstrual cycles. Someone else may need dietary adjustments or treatment for related conditions. The best HS plan is individualized, realistic, and flexible.

Questions to Ask Your Dermatologist About Biologics for HS

Patients considering biologic treatment should feel comfortable asking practical questions. Useful questions include: Which biologic fits my HS pattern and medical history? How will we measure success? What side effects should I watch for? What tests do I need before starting? How long should I try it before deciding whether it works? Can this be combined with surgery, antibiotics, or hormonal therapy? What happens if insurance denies coverage? Are biosimilars an option? What should I do if I get sick while taking it?

These questions are not annoying. They are exactly the kind of questions that turn treatment from a mystery into a plan. A good dermatologist would rather answer them early than have a patient quietly panic later in the parking lot with a prescription bag and seven tabs open on their phone.

Common Myths About Biologics for HS

Myth 1: Biologics Are Only for the Worst Cases

Biologics are generally used for moderate-to-severe HS, but that does not mean a patient must “suffer enough” before getting help. Earlier control of inflammation may help reduce disease burden and prevent worsening damage in some patients.

Myth 2: If One Biologic Fails, They All Will

Not necessarily. HS involves multiple inflammatory pathways. A patient who does not respond to one biologic may still respond to another, especially if it targets a different pathway. Switching therapies should always be guided by a healthcare professional.

Myth 3: Biologics Replace Every Other Treatment

Biologics can be central to HS care, but they do not automatically replace wound care, procedures, lifestyle adjustments, or other medications. Combination treatment is common.

Myth 4: Improvement Means You Can Stop Immediately

Stopping a biologic without medical guidance may allow HS symptoms to return. Any decision to pause, stop, or switch treatment should be made with a clinician.

Experience Section: What Living With HS Biologics Can Feel Like

For many people, the experience of starting a biologic for HS begins long before the first injection. It may start with years of being told the bumps are ingrown hairs, boils, acne, or hygiene problems. By the time biologics enter the conversation, patients are often tirednot just physically tired, but emotionally tired from explaining pain that other people cannot see. So when a dermatologist says, “We have a targeted treatment option,” it can feel like someone finally turned on the lights in a room where you have been bumping into furniture for years.

The first phase is usually paperwork and testing. Insurance approval can be frustrating, especially when a patient is ready to begin yesterday. Prior authorization, specialty pharmacy calls, copay cards, lab work, and delivery scheduling may feel like a side quest nobody requested. Patients often describe this stage as hopeful but irritating. It is hard to be patient when your skin is acting like it has its own dramatic weather system.

Then comes the first injection. Some people are comfortable right away; others need coaching, videos, a nurse visit, or a trusted person nearby. The injection itself is usually quick, but the mental build-up can be bigger than the moment. Many patients develop a routine: take the medication out of the refrigerator if instructed, gather supplies, clean the area, breathe, inject, dispose of the device safely, and then reward themselves with something small. Not a parade, maybe, but at least a snack. Dermatology should absolutely come with snacks.

The waiting period can be the hardest part. Biologics do not always produce instant results. A patient may still flare during the first weeks, which can feel discouraging. This is where tracking matters. Maybe the flares are shorter. Maybe pain is lower. Maybe drainage is less frequent. Maybe the underarm that usually explodes every month is quieter. Progress may look less like a movie makeover and more like a slow lowering of the volume.

When biologics help, the changes can be deeply meaningful. Patients may feel more comfortable walking, exercising, sitting, hugging, working, dating, or wearing clothes without planning around bandages. Some describe fewer emergency wardrobe changes, less fear of odor or drainage, and more confidence leaving the house. Pain reduction can also improve sleep, mood, and energy. These benefits are not cosmetic; they are life benefits.

Still, biologics are not perfect. Some patients respond only partially. Some lose response over time. Others switch medications because of side effects, convenience, pregnancy planning, infections, or insurance changes. A few may feel disappointed if old scars remain even after inflammation improves. That is why expectations matter. Biologics can calm active disease, but scarred tunnels may need procedural treatment.

The most successful patient experiences usually involve partnership. Patients report symptoms honestly, keep follow-up appointments, ask questions, and tell their doctor when the plan is not working. Clinicians adjust treatment, add procedures when needed, and help manage safety. HS may be chronic, but chronic does not mean hopeless. With biologics and a thoughtful care plan, many people finally get something HS rarely gives freely: breathing room.

Conclusion: Are Biologics for HS Worth Discussing?

Biologics for HS are one of the most important advances in hidradenitis suppurativa treatment. They are especially relevant for moderate-to-severe disease, recurring flares, painful inflammatory nodules, abscesses, tunnels, and HS that has not responded well enough to other therapies. Adalimumab, secukinumab, and bimekizumab give dermatologists more targeted ways to treat HS inflammation than ever before.

The best results usually come from personalized care. That may include biologics, procedures, wound care, pain control, lifestyle changes, and regular follow-up. HS can be stubborn, but modern treatment is no longer stuck in the “try an antibiotic and hope for the best” era. If HS is interfering with daily life, it is worth asking a dermatologist whether biologic therapy belongs in the treatment plan.

Note: This article is for educational purposes only and should not replace medical advice. Anyone considering biologics for HS should speak with a board-certified dermatologist or qualified healthcare provider.